Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of ARO-APOC3 in Adults With Dyslipidemia

ClinicalTrials.gov ID: NCT05413135

Public ClinicalTrials.gov record NCT05413135. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults With Dyslipidemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled participants initially received open-label ARO-APOC3 every three or six months at the assigned dose level of the parent study until a final dose of 25 mg was selected, at which point all participants transitioned to the selected dosing regimen of 25 mg every 3 months.

Study identification

NCT ID
NCT05413135
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Enrollment
418 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 6, 2022
Primary completion
Sep 21, 2025
Completion
Sep 21, 2025
Last update posted
May 11, 2026

2022 – 2025

United States locations

U.S. sites
30
U.S. states
16
U.S. cities
27
Facility City State ZIP Site status
Clinical Research Site 1 Beverly Hills California 90211
Clinical Research Site 2 Northridge California 91325
Clinical Research Site 3 Palm Springs California 92292
Clincal Research Site 4 Boca Raton Florida 33434
Clinical Research Site 5 Fort Lauderdale Florida 33308
Clinical Research Site 8 Miami Florida 33155
Clinical Research Site 6 Miami Florida 33173
Clinical Research Site 9 Miami Springs Florida 33166
Clinical Research Site 10 Pembroke Pines Florida 33024
Clinical Research Site 11 Port Orange Florida 32127
Clinical Research Site 12 Dunwoody Georgia 30338
Clinical Research Site 13 Minneapolis Minnesota 55455
Clinical Research Site 14 Tupelo Mississippi 38801
Clinical Research Site 15 Omaha Nebraska 68114
Clinical Research Site 16 Las Vegas Nevada 89121
Clinical Research Site 17 Long Island City New York 11106
Clinical Research Site 18 New Windsor New York 12553
Clinical Research Site 19 New York New York 10029
Clinical Research Site 20 Morehead City North Carolina 28557
Clinical Research Site 21 Fargo North Dakota 58104
Clinical Research Site 22 Marion Ohio 43302
Clinical Research Site 23 Maumee Ohio 43537
Clinical Research Site 24 Oklahoma City Oklahoma 73135
Clinical Research Site 25 Greenville South Carolina 29607
Clinical Research Site 26 Chattanooga Tennessee 37421
Clinical Research Site 29 Houston Texas 77002
Clinical Research Site 27 Houston Texas 77030
Clinical Research Site 28 Houston Texas 77099
Clinical Research Site 30 San Antonio Texas 78249
Clinical Research Site 31 Manassas Virginia 20110

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05413135, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 11, 2026 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05413135 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →